• Both Biden and Trump aim to lower drug prices to make healthcare more affordable, but Biden is expected to have a greater chance of success.
• We believe future healthcare policies are intertwined closely with the composition of the new Congress. A divided Congress may end up with little or no structural change and would be seen as largely positive for the healthcare sector.
• If a Blue Wave occurs, Biden’s ambition to remake the healthcare system may be more likely to pass. However, we believe that the near-term focus will still be on Covid-19 and any regulation or major changes may be put on hold until the worst of the crisis is over.
  
• We examine the impact on different healthcare industries under a Biden or Trump win. Below is a list of sector ETFs which investors may look out for.

Introduction

The healthcare sector consists of companies which provide medical services, medical equipment, drugs and medical insurance. It accounts for close to a fifth of U.S. GDP. Drug manufacturers make up the majority 37.7% of the sector. Other players include biotechnology firms and healthcare insurance providers, which account for 14.4% and 9.8% respectively.

Fundamentals

Covid-19 has had a mixed impact on the healthcare sector. Biotechnology and pharmaceutical companies may stand to benefit if they produce tests and vaccines for Covid-19. At the other end of the spectrum, the crisis has delayed elective surgeries and reduced visits to doctors for non-urgent treatment. A recent spike in Covid-19 cases may prompt states to reimpose elective surgery restrictions. Therefore, we believe that companies which do not have a foot in Covid-related development may continue to face headwinds. For insurers, massive unemployment may lead to cutbacks in insurance premiums. However, with the continued recovery in the labour market and potential fiscal stimulus, we believe the impact will be short-lived.

Longer term, demand for healthcare should remain anchored by an ageing population. Baby boomers – aged 65 and above – account for 16% of the U.S. population. The next age band of 45-64 years old accounts for 26% (Figure 4). These demographics should provide a steady stream of demand for pharmaceutical drugs and healthcare services over the next 10-20 years. Low interest rates, we believe, will support M&As by the huge pharmaceutical companies to gain access to new products.

U.S Elections – Policy Overview

Covid-19 has intensified the spotlight on the healthcare policies of Biden and Trump. We provide an overview of their proposed polices in Figure 1.

Potential impact on healthcare sector under different scenarios

Healthcare policies have always been tricky. There tend to be starkly different views on the trade-off between providing affordable healthcare to consumers and supporting the healthcare industries. Therefore, the composition of the new Congress matters as a unified government may increase the chances of pushing out aggressive policies. A split Congress may result in a stalemate, which generally favours the healthcare companies.

Sector Outlook

Private Insurers

We believe Trump may be positive for insurers. He is determined to weaken the ACA, which has various restrictions on insurers such as covering pre-existing conditions and no coverage limit. Further deregulation may increase flexibility for insurers and give them better control of premiums. Biden’s proposed policies could be mixed for insurers. Although he seeks to extend Medicare and Medicaid to more Americans, he is eyeing a government-run public option as an alternative for private insurance. We believe more clarity is needed as his ideas are still in the formation stage. The outlook for private insurers is thus highly uncertain.

Pharmaceuticals/Biotechnology

Both Biden and Trump aim to lower drug prices to make healthcare more affordable, but Biden is expected to have a greater chance of success. During Trump’s term, drug prices continued to grow y-o-y at around 2% (Figure 5). We believe his proposal to benchmark prices to those in the other countries is not feasible. Average prescription drug prices in the other developed countries stood at 15-40% of U.S. drug prices in 2018 (Figure 6). The trade-off will require either a high rebate rate of 60-70% from insurers or a 60% fall in revenue for drug manufacturers, both of which will be fiercely resisted by the industries. His previous attempt at reducing prices were also unsuccessful and we believe drug prices will continue to climb under his re-election.

Biden aims to allow Medicare to negotiate for lower drug prices with pharmaceutical companies. His success will depend on the leverage used to compel a company to provide competitive prices. However, we see greater chances of success in this ‘hard’ approach than Trump’s, as Medicare, being administered by a federal agency, may take tougher actions against companies for non-compliance.

The biotechnology industry may not be spared from the clampdown on drug pricing, though near-term opportunities remain. A Biden win will likely see a ramp-up of Covid testing. Investments in vaccine manufacturing should also continue, regardless of who becomes President. Therefore, biotechnology firms with Covid-related exposure should benefit in the near term.

Healthcare equipment makers

Biden aims to manufacture more medical equipment and other critical supplies to battle future pandemics and avoid reliance on other countries’ supplies. This bodes well for domestic equipment makers who may ramp up production. Trump hopes to boost domestic manufacturing but has not flagged healthcare equipment specifically.

Healthcare service providers

We believe healthcare service providers will benefit either which way, more so under Biden. Biden aims to expand Medicare and Medicaid to more Americans, which should lift demand for healthcare services. His plan to increase cost-sharing reductions for middle-class Americans may also lead to higher adoption of healthcare services. Trump aims to promote telehealth services to expand healthcare access to rural areas and Medicare. Therefore, providers with telehealth growth may see greater demand for their services.

Valuation/ Relative Strength

Current forward P/E ratio for the healthcare sector stands at 17.8x. This is below its 5-year historical average of 20.4x. Forward dividend yield stands at 1.68%, which is in line with its 5-year average of 1.66%. This indicates the sector is more of a growth than dividend play. Its performance has been roughly in line with the market. About 69.8% of S&P 500 healthcare stocks are trading above their 200-day moving averages, close to the 68.9% for the S&P 500.

RECOMMENDATION:

We believe future healthcare policies are intertwined closely with the composition of the new Congress. A divided Congress will likely push out big legislation and we may end up with little or no structural change. This would remove uncertainty for the sector and would be seen as largely positive. If a Blue Wave occurs, Biden’s ambition to remake the healthcare system may be more likely to pass. However, we believe that the near-term focus will still be on Covid-19 and any regulation or major changes may be put on hold until the worst of the crisis is over. Therefore, we do not expect any significant overhaul of the system over the next 1-2 years. Under both candidates, healthcare adoption may rise, but potentially more so under Biden due to his plans to get more people insured.

Disclaimer
Important Information: This report is prepared and/or distributed by Phillip Securities Research Pte Ltd (“Phillip Securities Research”), which is a holder of a financial adviser’s licence under the Financial Advisers Act, Chapter 110 in Singapore.
By receiving or reading this report, you agree to be bound by the terms and limitations set out below. Any failure to comply with these terms and limitations may constitute a violation of law. This report has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this report by mistake, please delete or destroy it, and notify the sender immediately.
The information and any analysis, forecasts, projections, expectations and opinions (collectively, the “Research”) contained in this report has been obtained from public sources which Phillip Securities Research believes to be reliable. However, Phillip Securities Research does not make any representation or warranty, express or implied that such information or Research is accurate, complete or appropriate or should be relied upon as such. Any such information or Research contained in this report is subject to change, and Phillip Securities Research shall not have any responsibility to maintain or update the information or Research made available or to supply any corrections, updates or releases in connection therewith.
Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this report are as of the date indicated and are subject to change at any time without prior notice. Past performance of any product referred to in this report is not indicative of future results.
This report does not constitute, and should not be used as a substitute for, tax, legal or investment advice. This report should not be relied upon exclusively or as authoritative, without further being subject to the recipient’s own independent verification and exercise of judgement. The fact that this report has been made available constitutes neither a recommendation to enter into a particular transaction, nor a representation that any product described in this report is suitable or appropriate for the recipient. Recipients should be aware that many of the products, which may be described in this report involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made, unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.
Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of any product. Any decision to purchase any product mentioned in this report should take into account existing public information, including any registered prospectus in respect of such product.
Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may provide an array of financial services to a large number of corporations in Singapore and worldwide, including but not limited to commercial / investment banking activities (including sponsorship, financial advisory or underwriting activities), brokerage or securities trading activities. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have participated in or invested in transactions with the issuer(s) of the securities mentioned in this report, and may have performed services for or solicited business from such issuers. Additionally, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have provided advice or investment services to such companies and investments or related investments, as may be mentioned in this report.
Phillip Securities Research or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report may, from time to time maintain a long or short position in securities referred to herein, or in related futures or options, purchase or sell, make a market in, or engage in any other transaction involving such securities, and earn brokerage or other compensation in respect of the foregoing. Investments will be denominated in various currencies including US dollars and Euro and thus will be subject to any fluctuation in exchange rates between US dollars and Euro or foreign currencies and the currency of your own jurisdiction. Such fluctuations may have an adverse effect on the value, price or income return of the investment.
To the extent permitted by law, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may at any time engage in any of the above activities as set out above or otherwise hold an interest, whether material or not, in respect of companies and investments or related investments, which may be mentioned in this report. Accordingly, information may be available to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, which is not reflected in this report, and Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may, to the extent permitted by law, have acted upon or used the information prior to or immediately following its publication. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited its officers, directors, employees or persons involved in the issuance of this report, may have issued other material that is inconsistent with, or reach different conclusions from, the contents of this report.
The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities Research to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.
This report is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this report may not be suitable for all investors and a person receiving or reading this report should seek advice from a professional and financial adviser regarding the legal, business, financial, tax and other aspects including the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.
This report is not intended for distribution, publication to or use by any person in any jurisdiction outside of Singapore or any other jurisdiction as Phillip Securities Research may determine in its absolute discretion.
IMPORTANT DISCLOSURES FOR INCLUDED RESEARCH ANALYSES OR REPORTS OF FOREIGN RESEARCH HOUSES Where the report contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact Phillip Securities Research (and not the relevant foreign research house) in Singapore at 250 North Bridge Road, #06-00 Raffles City Tower, Singapore 179101, telephone number +65 6533 6001, in respect of any matters arising from, or in connection with, the analyses or reports; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore who is not an accredited investor, expert investor or institutional investor, Phillip Securities Research accepts legal responsibility for the contents of the analyses or reports.

If Distribution is to Australian Investors This report is produced by Phillip Securities Pte Ltd and is being distributed in Australia by Phillip Capital Limited (Australian Financial Services License No. 246827). This report contains general securities advice and does not take into account your personal objectives, situation and needs. Past performance is not a reliable indicator of future performance. Please read the Disclosures and Disclaimers set out above. By receiving or reading this report, you agree to be bound by the terms and limitations set out above. Any failure to comply with these terms and limitations may constitute a violation of law. This report has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this report by mistake, please delete or destroy it, and notify the sender immediately.